FDA reviewers back approval of Merck's blood-clot drug

01/13/2014 | Reuters · Medscape (free registration)

Ahead of an FDA advisory panel meeting Wednesday, FDA reviewers recommended the approval of Merck & Co.'s experimental blood-clot drug Zontivity, or vorapaxar, for prevention of stroke, cardiac arrest and cardiac-related death in patients who recently had a heart attack. The recommendation was based on "robustly positive" data from the TRA 2P trial.

View Full Article in:

Reuters · Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY